IDEXX Laboratories Stock: $876 Target Backed by Cancer Dx Adoption Across 7,500 Practices
IDEXX Laboratories (IDXX) exceeded Q1 2026 revenue and EPS estimates, driven by its Companion Animal Group and increasing adoption of its inVue Dx and Cancer Dx platforms, with the latter now used in 7,500 practices. Despite a slight dip in U.S. clinical visits, diagnostic frequency boosted growth, leading IDEXX to raise its full-year guidance. TIKR's mid-case model projects an $876 target by December 2030, suggesting a 57% total return, while Wall Street analysts maintain a split rating with a mean target of $709.
Insulet launches Omnipod 5 insulin system in Spain By Investing.com
Insulet Corporation has officially launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data management platform in Spain, making it the 20th country for Omnipod 5 and 26th market overall for Insulet's Omnipod products. This expansion targets Spain's 189,000 individuals with type 1 diabetes, enabling automated insulin delivery and data management for better diabetes care. Despite the aggressive international growth and 32% revenue increase, InvestingPro analysis suggests the stock is currently overvalued, while the company also faces recent product recall concerns and new analyst coverage.
IDEXX Laboratories stock holds its focus on diagnostics. Investors watch the business mix.
IDEXX Laboratories continues to focus on companion-animal diagnostics, with its business model emphasizing recurring revenue from instruments, reagents, and services for veterinarians and water-testing workflows. The company's U.S. Nasdaq listing and its core identity in animal health are key factors for investors, who primarily monitor revenue quality, margins, and operational execution rather than one-off product launches. The company's veterinary diagnostics platform remains its best-known commercial engine, though it also serves water and livestock markets.
If You Invested $1,000 in IDEXX Laboratories (IDXX)
This article analyzes the historical performance of investing $1,000 in IDEXX Laboratories (IDXX) over different periods, showcasing growth and declines. It details IDXX's business, including its focus on pet healthcare innovation, diagnostic products, software, and telemedicine, and its global presence in veterinary medicine and public health. The article also provides a financial overview and governance insights into the NASDAQ-listed S&P 500 company.
Enterprise value to EBIT forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX
This article focuses on the enterprise value to EBIT forward of IDEXX Laboratories, Inc. (NASDAQ: IDXX). It presents financial data for the company within the TradingView platform, specifically under its section for financial information and market data.
IDEXX Laboratories focuses on diagnostics growth as investors watch long-term demand
IDEXX Laboratories continues to expand its veterinary and water diagnostics, with a business model heavily reliant on recurring revenue from consumables and services. The company benefits from rising pet ownership, increased spending on pet healthcare, and technological advancements in diagnostics. Its long-term value is driven by the durability of pet healthcare demand and steady revenue streams.
Price to sales forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX
This article focuses on the "Price to sales forward" metric for IDEXX Laboratories, Inc. (NASDAQ: IDXX) as presented on the TradingView platform. It highlights financial data and market information relevant to the company. The content appears to be a snapshot from a financial data provider, primarily displaying navigation and data source acknowledgements rather than in-depth analysis.
Price to earnings forward of IDEXX Laboratories, Inc. – LSE:0J8P
This article provides financial information for IDEXX Laboratories, Inc. (LSE:0J8P), specifically its price to earnings forward. It is presented in the context of TradingView's platform, offering an overview of the company's financials for the London Stock Exchange. The content is primarily a data placeholder within a financial information service.
ILMN - Illumina Inc Volatility & Greeks
This article provides a detailed snapshot of Illumina Inc. (ILMN) financial and stock performance data as of July 2, 2026. It includes key metrics such as market capitalization, income, sales, various P/E ratios, EPS growth rates, insider and institutional ownership, profitability margins, and volatility indicators. The data highlights recent price changes, trading volumes, and performance over different periods.
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
IDEXX Laboratories, Inc. (NASDAQ: IDXX) is scheduled to release its 2026 second quarter financial results on Tuesday, August 4, 2026, before market open, followed by an analyst conference call at 8:30 a.m. ET. The company will also host its 2026 Investor Day on Thursday, August 13, 2026, requiring advance registration for in-person attendance. IDEXX, a global leader in pet healthcare innovation, provides diagnostic and software products and services to the veterinary community and related sectors.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) saw its stock rally by 3.76% to $557.80 on Thursday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. This marks the second consecutive day of gains for the company's shares. The strong performance occurred during a mixed trading session for the broader stock market.
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
IDEXX Laboratories, Inc. (NASDAQ: IDXX) will release its 2026 second quarter financial results on Tuesday, August 4, 2026, before the market opens, followed by an analyst conference call. The company will also host its 2026 Investor Day on Thursday, August 13, 2026, at its Westbrook, Maine headquarters. IDEXX, a global leader in pet healthcare innovation, provides diagnostic and software products and services to the veterinary community and is a member of the S&P 500® Index.
IDXX - Idexx Laboratories Inc Volatility & Greeks
This article provides a detailed financial overview of Idexx Laboratories Inc. (IDXX), including its current stock performance, key financial metrics, volatility indicators, and analyst recommendations. It covers various data points from market capitalization to insider transactions and performance across different timeframes, offering a comprehensive snapshot of the company's financial health and stock behavior.
DGX - Quest Diagnostics Inc Options
This article provides a comprehensive financial overview of Quest Diagnostics Inc. (DGX), including its market performance, valuation metrics, dividend information, and growth rates. Key financial data points such as P/E ratio, market capitalization, sales, and various performance indicators are detailed.
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
IDEXX Laboratories will announce its second-quarter 2026 financial results on Thursday, August 6, 2026, followed by a webcast and conference call for investors. Interested parties can access the press release and financial data on the company's website. The call will also be available for replay.
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has announced that it will release its 2026 second quarter financial results on Tuesday, August 4, 2026, before market open, followed by an analyst conference call at 8:30 a.m. ET. The company will also host its 2026 Investor Day on Thursday, August 13, 2026, at its Westbrook, Maine headquarters. Both events will have webcast access available on the IDEXX investor relations website.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) shares advanced 2.12% to $537.58, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average decline. This rise broke a three-day losing streak for the company's stock.
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors
Shares of IDEXX Laboratories Inc. (IDXX) fell 1.77% on Tuesday, closing at $526.44. This underperformance occurred on a generally positive day for the stock market, with both the S&P 500 and Dow Jones Industrial Average posting gains. This marks the third consecutive day of losses for IDEXX stock.
Could Insulet’s (PODD) Russell 2500 Debut Quietly Reframe the Omnipod Investment Narrative?
Insulet Corporation (PODD) has been added to the Russell 2500 Index and Russell 2500 Growth Benchmark, which could attract passive fund inflows and institutional attention. The company also appointed Jonathan Mazelsky, former IDEXX Laboratories CEO, to its board, bringing extensive healthcare and diagnostics experience. These developments are expected to increase visibility for Insulet's Omnipod platform and its potential for deepening its role in diabetes care, though near-term drivers remain Omnipod 5 uptake and algorithm enhancements.
Insulet (PODD) Appoints Jay Mazelsky To Its Board Of Directors
Insulet (PODD) has appointed Jay Mazelsky to its Board of Directors, bringing his executive and board expertise from IDEXX Laboratories and Philips Healthcare. This appointment is expected to add valuable healthcare technology and governance experience, which may influence Insulet's product priorities and operational decisions in the diabetes care market. Investors will be watching for how this new board member impacts future product strategy, partnerships, or capital allocation.
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock decreased by 2.82% on Monday, closing at $535.93. This underperformance occurred on an otherwise positive trading day where the S&P 500 Index and the Dow Jones Industrial Average both saw gains. This marks the second consecutive day of losses for IDEXX Laboratories Inc. shares.
IDEXX Laboratories opens the week with a clear consensus, NASDAQ-100 shares in a steady trend
IDEXX Laboratories (IDXX) begins the week with a strong analyst consensus and a stable presence on the NASDAQ-100. Analysts largely maintain "Buy" or "Outperform" ratings, projecting mid-single-digit percentage upside and steady revenue growth, supported by the company's dominant position in companion-animal diagnostics and recurring revenue streams. The stock currently trades at a premium P/E multiple due to its robust business model and essential role in the veterinary diagnostics market.
A419U9 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Bolt Biotherapeutics, Inc. (A419U9) stock, including analyst price targets and ratings. It also details the company's financial performance, such as recent earnings and revenue, upcoming earnings dates, and employee count. The article notes that A419U9 does not pay dividends and offers information on how to trade its stock.
IDEXX Laboratories opens the week with earnings focus, shares steady
IDEXX Laboratories is starting the week with an earnings focus, as its next earnings date is listed by MarketBeat. The company's stock closed at $554.94 on Wednesday, and its March 2026 quarter revenue was reported at $1.14 billion, up 14.3% year-over-year, with EPS of $3.47 against a consensus estimate of $3.42. The next earnings date for IDEXX Laboratories is August 5, 2026.
IDEXX Laboratories, Inc. Actuals & Estimates (NASDAQ:IDXX)
This article provides a detailed overview of IDEXX Laboratories, Inc. (NASDAQ: IDXX) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions regarding its stock ticker, volatility, market capitalization, earnings reports, revenue, net income, dividends, and employee count. The article also touches upon technical analysis and investment considerations for potential investors.
IDEXX Laboratories, Inc. Actuals & Estimates (VIE:IDXX)
This article provides an overview of IDXX Laboratories, Inc. (VIE:IDXX) stock performance, financial actuals, and analyst estimates. It includes current stock prices, historical highs and lows, market capitalization, volatility, and details on recent earnings and revenue, along with forecasts. The company's next earnings report is expected on August 4, 2026.
IDEXX Laboratories sets the pace with raised 2026 guidance, analysts back the stock
IDEXX Laboratories has raised its 2026 revenue and EPS targets after a strong first quarter, reporting approximately $1.14 billion in revenue, up 14% year-on-year. Wall Street analysts maintain a "Buy" consensus for the stock, expecting double-digit earnings growth into mid-year, with an average 12-month price target of around $709, implying a mid-20% upside. The company, which specializes in veterinary diagnostics, revised its full-year revenue guidance to between $4.675 billion and $4.760 billion, and EPS to between $14.45 and $14.90.
Enterprise value to EBITDA forward of IDEXX Laboratories, Inc. – DUS:IX1
This article provides financial information for IDEXX Laboratories, Inc. (DUS:IX1) on the TradingView platform, specifically focusing on its enterprise value to EBITDA forward metric. The content highlights that the market for this stock was closed with no trades recorded.
Insulet Appoints Former IDEXX CEO Jay Mazelsky to Board of Directors
Insulet Corporation has appointed Jonathan "Jay" Mazelsky, former CEO of IDEXX Laboratories, to its Board of Directors, effective July 1, 2026. Mazelsky's extensive experience in global medical technology and diagnostics is expected to help Insulet expand its Omnipod insulin delivery systems and strengthen its leadership in diabetes care. His appointment reflects Insulet's ongoing strategy to grow its presence in the diabetes technology market and explore new therapeutic applications for its wearable Pod platform.
Insulet names Jonathan J. Mazelsky as director effective July 1, 2026
Insulet (PODD) has announced the appointment of Jonathan J. Mazelsky as a Class II director, effective July 1, 2026. Mr. Mazelsky, who previously served as Executive Chair of IDEXX, will stand for election at the company's 2027 Annual Meeting. The appointment details, including his background and past roles at Philips Healthcare, Agilent Technologies, and Hewlett Packard, were disclosed in an SEC filing.
Insulet appoints Jay Mazelsky to board of directors
Insulet Corporation announced the appointment of Jonathan Mazelsky to its board of directors as an independent director, effective July 1, 2026. This appointment comes as Insulet's stock trades near its 52-week low despite strong fundamentals, and Mazelsky brings extensive leadership experience from IDEXX Laboratories and Philips Healthcare. His addition is expected to provide valuable guidance as Insulet navigates market challenges and continues its product development.
Jay Mazelsky joins Insulet (NASDAQ: PODD) board as independent director
Insulet Corporation announced the appointment of Jonathan J. (Jay) Mazelsky to its Board of Directors as a Class II independent member, effective July 1, 2026. Mazelsky, former President and CEO of IDEXX Laboratories, will receive an initial restricted stock unit grant worth $216,548 and cash compensation. The company highlights his extensive experience in leadership roles at various healthcare and technology companies, which is expected to support Insulet's growth and mission to simplify life for people with diabetes.
Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
Insulet Corporation, a leader in tubeless insulin pump technology, has announced the appointment of Jonathan J. Mazelsky to its Board of Directors, effective July 1, 2026. Mr. Mazelsky, a seasoned executive with a strong background in medical technology and animal health diagnostics, is expected to bring valuable insights to Insulet's continued growth and efforts to expand access to its Omnipod products. His appointment is aimed at further strengthening Omnipod's market leadership and enhancing shareholder value.
Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
Insulet Corporation announced the appointment of Jonathan ("Jay") Mazelsky to its Board of Directors, effective July 1, 2026. Mazelsky, former CEO of IDEXX Laboratories, brings extensive experience in leadership and driving growth in the healthcare sector. His appointment is expected to bolster Insulet's mission to expand access and strengthen the leadership position of its Omnipod products for people with diabetes.
Insulet adds Jay Mazelsky to board as Omnipod expands
Insulet Corporation announced the appointment of Jonathan "Jay" Mazelsky to its Board of Directors, effective July 1, 2026. Mazelsky brings extensive experience from his tenure as CEO of IDEXX Laboratories, where he significantly grew revenues and stock price. His expertise is expected to be integral as Insulet continues to expand access and strengthen the leadership position of its Omnipod brand in tubeless insulin pump technology.
Why IDEXX Laboratories Stock Looks Undervalued After Raising Its 2026 EPS Outlook to $15
IDEXX Laboratories (IDXX) beat Q1 2026 revenue and EPS estimates, driven by strong growth in veterinary diagnostics, particularly from its Companion Animal Group. The company raised its full-year 2026 guidance, with EPS expected between $14.45 to $14.90, and placed 1,100 inVue Dx analyzers, confirming its structural earnings growth trajectory. TIKR's mid-case model suggests the stock is undervalued, projecting an 11% annualized return to $862 by December 2030.
Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
Insulet Corporation has announced the appointment of Jonathan ("Jay") Mazelsky to its Board of Directors as an independent director, effective July 1, 2026. Mazelsky brings extensive leadership experience from IDEXX Laboratories and Philips Healthcare, where he significantly contributed to revenue growth and strategic development. His expertise is expected to help Insulet expand access and strengthen the leadership position of its Omnipod brand in diabetes care.
Enterprise value to revenue forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX
This article focuses on the enterprise value to revenue forward for IDEXX Laboratories, Inc. (NASDAQ:IDXX). It appears to be a financial data point from TradingView, indicating that the market for IDXX was closed at the time of publication and there were no trades. The content primarily highlights the financial metric for the company.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) shares rose 1.45% to $549.16 on Wednesday, outperforming the S&P 500 Index while the Dow Jones Industrial Average also saw gains. This increase broke a two-day losing streak for the company's stock.
Danaher plans July 21 earnings call, slide deck at 6 a.m. ET
Danaher (NYSE:DHR) announced it will host its second quarter 2026 earnings conference call on July 21, 2026, starting at 8:00 a.m. ET. The company will discuss financial performance and future expectations, with accompanying slide presentations and earnings materials available on its website's "Investors" section from 6:00 a.m. ET. A webcast and replay will also be accessible for investors.
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock fell by 2.91% on Monday, closing at $545.73. This underperformance occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index declined. The company's stock is now 29.12% below its 52-week high achieved in November.
A Small Upgrade Could Have a Big Impact for IDEXX Customers
IDEXX Laboratories, Inc. (NASDAQ: IDXX) is enhancing its diagnostic offerings with two key upgrades. The company is expanding its Fecal Dx antigen testing platform to detect taeniid tapeworm species, providing broader parasite detection at no extra cost to customers. Additionally, its SDMA renal biomarker will be integrated into Catalyst CLIPs, aiming to improve early kidney function assessment for veterinarians in the US and Canada.
IDEXX Laboratories Stock - Saturday deep dive into the long-term business model
This article provides a long-term deep dive into IDEXX Laboratories, focusing on its business model, revenue drivers, and structural tailwinds in animal health rather than short-term news. It highlights the company's strong position in veterinary diagnostics, its recurring revenue streams from instruments, consumables, and software, and its significant growth potential due to rising pet ownership and increased spending on veterinary care. Key financial data and company information are also provided.
IDEXX Laboratories Stock Is Down 16% in 2026: Does the Q1 Beat Make It a Buy at $562?
IDEXX Laboratories reported a strong Q1 2026, beating revenue estimates by 14% and raising full-year guidance, despite a 1% decline in U.S. clinical visits. The company's recurring diagnostic revenue grew 11% organically, driven by increased diagnostic frequency and utilization per visit. Analysts remain divided, with some seeing structural growth regardless of visit volumes, while others are concerned about consumer spending on wellness, but the mean price target suggests a 26% upside.
ELAN - Elanco Animal Health Inc Stock Price and Quote
This article provides comprehensive financial data, news, and analyst ratings for Elanco Animal Health Inc (ELAN). It covers the company's stock performance, key financial metrics, recent corporate announcements including the launch of Elanco Ventures, new product approvals, and insider trading activities.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) saw its stock rally by 2.93% to $562.09, outperforming the broader market during a positive trading session. The S&P 500 and Dow Jones Industrial Average also rose. Despite the gain, IDEXX stock remains 27.00% below its 52-week high.
IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of IDEXX Laboratories Inc (IDXX), detailing its current price momentum, support and resistance levels, and various technical indicator readings. It notes that IDXX's current price momentum score is 6.57, suitable for range-bound swing trading, and highlights that indicators and moving averages generally suggest a "Sell" signal for the stock. The analysis emphasizes that these are for reference only and not financial advice.
IDEXX Laboratories Inc (IDXX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend and stock split history for IDEXX Laboratories Inc (IDXX). It notes that IDEXX has not distributed any dividends over the past five years and that there is no data available for stock splits. The page also presents current stock performance metrics and general company information.
IDEXX Laboratories Inc (IDXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for IDEXX Laboratories Inc (IDXX) based on business segments and regional contributions. It highlights that CAG Diagnostics recurring revenue is the largest segment, comprising 79.17% of total revenue, with the United States contributing the majority of regional revenue at 63.96%. The data presented helps in understanding the company's financial performance and revenue sources.
IDEXX Laboratories Inc (IDXX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of IDEXX Laboratories Inc (IDXX), indicating its current valuation score is 7.34, placing it 168th out of 204 in the Healthcare Equipment & Supplies industry. The P/E ratio is noted at 39.91, which is below its recent high but above its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not been disclosed by the company.
